Wednesday, 27 March 2019

Parkinson’s Disease Therapeutics Market : Business Strategy In Global Industry To 2025

ResearchMoz presents professional and in-depth study of "Parkinson’s Disease Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025".

Parkinson’s Disease Therapeutics Market - Overview

This report on Parkinson’s disease therapeutics market studies the current as well as future prospects of the market globally. Stakeholders of the market include companies and intermediaries engaged in the manufacturing, commercialization, providing therapeutic drugs for treatment of Parkinson’s disease, as well as new entrants planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global Parkinson’s disease therapeutics market with respect to the leading market segments based on drug class, route of administration, distribution channel, and geography.

Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1772203

The global Parkinson’s disease therapeutics market is divided into four segments on the basis of drug class, route of administration, distribution channel, and geography. Based on drug class, the market has been further segmented into Levodopa combination, dopamine agonists, MAO-B Inhibitors, COMT Inhibitors, and others. In terms of route of administration, the market has been classified into oral, transdermal, subcutaneous, intestinal infusion, and others. The Parkinson’s disease therapeutics market has also been studied from the point of distribution channel, based on which the market has been bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy.

Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of Parkinson’s disease. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR) percentage for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the Parkinson’s disease therapeutics market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global Parkinson’s disease therapeutics market.

Geographically, Parkinson’s disease therapeutics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2015 to 2025, along with their respective CAGR for the forecast period from 2017 to 2025, considering 2016 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thus presenting a thorough examination of the overall competitive scenario of the global Parkinson’s disease therapeutics market.

Major players operating in the global Parkinson’s disease therapeutics market are AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc, which exhibit the widest geographical outreach. Other prominent players operating in the global market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.

The global Parkinson’s disease therapeutics market is segmented as follows:

By Drug Class

    Levodopa Combination
    Dopamine Agonists
    MAO-B Inhibitors
    COMT Inhibitors
    Others

By Route of Administration

    Oral
    Transdermal
    Subcutaneous
    Intestinal Infusion
    Others

By Distribution Channel

    Hospital Pharmacy
    Retail Pharmacy
    Online Pharmacy

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1772203

By Geography

    North America
        U.S.
        Canada
    Europe
        U.K.
        Germany
        France
        Italy
        Spain
        Rest of Europe
    Asia Pacific
        China
        India
        Japan
        Australia & New Zealand
        Rest of Asia Pacific
    Latin America (LATAM)
        Brazil
        Mexico
        Rest of LATAM
    Middle East & Africa
        GCC
        South Africa
        Rest of Middle East & Africa

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

No comments:

Post a Comment